resTORbio

Showing 1 posts of 1 posts found.

shutter

resTORbio shuts down Phase 3 trial in clinically symptomatic respiratory illness

November 18, 2019
Research and Development, Sales and Marketing pharma, resTORbio

US firm resTORbio has revealed its intention to terminate a Phase 3 trial of its oral, selective TORC1 inhibitor RTB101 …

Latest content